Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components.

ABSTRACT:

Aims

Tocilizumab has a direct effect on inflammatory markers. Therefore, composite measures for disease activity assessment in rheumatoid arthritis (RA) using these inflammatory markers may not be suitable for tocilizumab treatment. We used a modelling approach to describe the tocilizumab exposure-response relationship and to investigate the different dynamics of the individual components of the routinely used continuous composite measures.

Methods

Pharmacokinetic (PK), clinical and laboratory data were obtained from a prospective, observational, single-centre study involving 35 subjects with RA treated with intravenous tocilizumab. A population PK/pharmacodynamic analysis was performed using nonlinear mixed effects models.

Results

The population for model development

SUBMITTER: Bastida C 

PROVIDER: S-EPMC6624405 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature